Robin Elliott
Amgen Inc.
Public scientific profile · Unclaimed
Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.
Top expertise
Ion Channels and Receptors
Strong evidence · 3 supporting papers · latest 2019
Ion channel regulation and function
Strong evidence · 3 supporting papers · latest 2019
Asthma and respiratory diseases
Strong evidence · 2 supporting papers · latest 2019
Bone health and treatments
Solid evidence · 2 supporting papers · latest 2008
Bone Metabolism and Diseases
Solid evidence · 2 supporting papers · latest 2008
Nicotinic Acetylcholine Receptors Study
Solid evidence · 1 supporting paper · latest 2015
Venomous Animal Envenomation and Studies
Solid evidence · 1 supporting paper · latest 2015
Toxin Mechanisms and Immunotoxins
Solid evidence · 1 supporting paper · latest 2013
Publications (6)
Pharmaceutical Optimization of Peptide Toxins for Ion Channel Targets: Potent, Selective, and Long-Lived Antagonists of Kv1.3
2015DOIPMID 26288216
Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate Airways
2019DOIPMID 30837866
Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide are Potent TMEM16A Antagonists that Fully Bronchodilate Airways
2018DOI
Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL
2008DOIPMID 19016581
Generation and Characterization of Fully Human Monoclonal Antibodies Against Human Orai1 for Autoimmune Disease
2013DOIPMID 23475901
197 POSTER Denosumab is a selective inhibitor of human receptor activator of NF-kB ligand that blocks osteoclast formation in vitro and in vivo
2006DOI
Organizations in sourced records
Affiliation evidence only — not confirmed current employment.
- Amgen Inc.
Source: OpenAlex · retrieved 2026-09-29